Synthesis, analysis and biological evaluation of novel steroidal estrogenic prodrugs for the treatment of breast cancer

Pharmaceutical Biology

Volumn 42, Issue 4-5, 2004, Pages 367-373

  Sadeghi Aliabadi, Hojjat ^a   Brown, John E ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Breast cancer; Cancer chemotherapy; Doxorubicin; Drug targeting; Estrogen receptor; Estrogenic prodrugs; K562; MCF 7; MCF 7ADR; MT 1; Spacer group; Steroids

Indexed keywords

17 AMINOXYESTRONE DOXORUBICIN PRODRUG; 3 ESTRONE DODECANEDIOYL ESTER DOXORUBICIN PRODRUG; DOXORUBICIN; DOXORUBICIN DODECANEDIOYL ESTER; ESTROGEN RECEPTOR; ESTRONE 17 AMINODODECANE DOXORUBICIN PRODRUG; ESTRONE ADIPOYL ESTER DOXORUBICIN PRODRUG; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CARDIOMYOPATHY; CELL STRAIN K 562; CELL STRAIN MCF 7; CHEMOSENSITIVITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE;

MINK CELL FOCUS-FORMING VIRUS;

EID: 10344250434     PISSN: 13880209     EISSN: None     Source Type: Journal    
DOI: 10.1080/13880200490519686     Document Type: Article

References (15)

1. Albert A (1985): Selective Toxicity, 7th ed. London, Chapman and Hall.
2. Baum M, Ziv Y, Colletta A (1991): Prospects for the chemoprevention of breast cancer. Br Med Bull 47: 493-503.
3. Bielack SS, Erttmann R, Winkler K, Landbeck G (1989): Doxorubicin-effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 25: 873-882.
4. Cooper GM (1992): Elements of Human Cancer. London, Jones and Bartlett Publishers International, pp. 4-61.
5. Eisenbrand G, Berger MR, Fischer J, Schneider MR, Tang W, Zeller WJ (1988): Development of more selective anticancer nitrosoureas. Anti-cancer Drug Design 2: 351-359.
6. Ferguson JE, Dodwell DJ, Seymoure AM, Richards MA, Howell A (1993): High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. Br J Cancer 67: 825-829.
7. Hambly RJ, Bibby MC, Double JA (1994): Establishment and characterisation of three new human breast cancer cell lines for anticancer drug evaluation in vitro. Br J Cancer 69(Supp. 21): 31.
8. Hartman NG, Angelucci F, Suarato A (1988): United Kingdom Patent GB 2201419 A (Application Number 8704236).
9. Jabbar SAB, Twentyman PR, Watson JV (1989): The MTT assay underestimates the growth inhibitory effects of Interferon. Br J Cancer 60: 523-528.
10. Kuo DYS, Runowicz CD (1995): Gynecological effects of tamoxifen. Med Oncol 12: 87-94.
11. Manns JE, Double JA, Brown JE (1993): Cell uptake and estrogen receptor binding affinities of novel triphenylethylene compounds. J Pharm Pharmacol 45: 1127.
12. Masquelier M, Baurain R, Trouet A (1980): Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion. J Med Chem 23: 1166-1170.
13. Osborne CK, Hobbs K, Clark GM (1995): Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45: 584-590.
14. Pasman PC, Schouten HC (1993): Multidrug-resistance mediated by P-glycoprotein in hematological malignancies. Netherlands J. Med 42: 218-231.
15. Wittliff JL (1984): Steroid-hormone receptors in breast cancer. Cancer 53: 630-643.